These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38129808)

  • 1. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
    Du C; Chen Y; Zhou Y; Zheng D; Zhao J; Tang J; Wu Y; Tu Z
    BMC Cancer; 2023 Dec; 23(1):1260. PubMed ID: 38129808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
    Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.
    Zeng L; Zhou Y; Zhang X; Xu Q; Zhou C; Zeng F; Jiang W; Wang Z; Deng L; Yang H; Liu L; Xiong Y; Zhang B; Yang N; Zhang Y
    Lung Cancer; 2023 Apr; 178():134-142. PubMed ID: 36858002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.
    Razi SS; Nguyen D; Villamizar N
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2469-2483.e4. PubMed ID: 31928821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
    Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
    Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
    Liu K; Chen HL; You QS; Huang JF; Wang H
    Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
    Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
    Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IIIB-T4 non-small cell lung cancer: indications and results of surgical treatment.
    Lucchi M; Viti A; Melfi F; Ambrogi M; Givigliano F; Dini P; Mussi A
    J Cardiovasc Surg (Torino); 2007 Jun; 48(3):369-74. PubMed ID: 17505443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
    Yan D; Wei P; An G; Chen W
    J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer.
    Chen Y; Yan B; Zhang R; Zhao G; You J
    Heliyon; 2023 Sep; 9(9):e19818. PubMed ID: 37809935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
    Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
    Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
    Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
    Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.